- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Fischer's Q2 revenues climb 21%
Fischer Imaging saw revenues jump 21% for its second quarter (end-June)due to continued success in selling systems through its OEM partners.The Denver company also saw net income more than double in theperiod. For the quarter, Fischer reported sales of
Fischer Imaging saw revenues jump 21% for its second quarter (end-June)due to continued success in selling systems through its OEM partners.The Denver company also saw net income more than double in theperiod.
For the quarter, Fischer reported sales of $21.9 million, upsharply from the $18.1 million posted in the second quarter of1995. Net income stood at $946,000, compared with $397,000 inthe same period the year before.
Fischer chairman and CEO Morgan Nields reported that Fischer'sSenoScan full-field digital mammography program is moving forward:Fischer is planning to ship its second clinical trial unit inthe next several weeks, with clinical trials to follow. Fischerplans to submit a regulatory application for the system in thesecond half of this year, with clearance expected in 1997.
Fischer earlier this month completed a secondary stock offeringthat raised $13.5 million. The company is now virtually debt-freeand has cash on hand to fund growth opportunities, according toCFO Jim Newcomb.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
